Natera

NTRA

Market cap $33B

Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarter all in the sector.

Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing.

Natera, Inc. ( NTRA ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. So last run of the day.

Natera, Inc. ( NTRA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division So I am going to go ahead and kick it off. I'm Tycho Peterson from the Jefferies Life Science team.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours during the company's fourth annual Volunteer Month. This initiative takes place each October and is organized by Natera Nurtures, the company's employee resource group dedicated to community service and philanthropy. Natera encourages employees to live one of its core values, Be Ready to Change the Wo.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Natera's oncology testing portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform. The integration enables seamless electronic ordering and results delivery for Natera's oncology tes.

Natera, Inc. ( NTRA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Conference Call Participants Noah Kava - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Puneet Souda - Leerink Partners LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Welcome to Natera's 2025 Third Quarter Financial Results Conference Call.

While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Natera (NTRA) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter.